07:00 , Jul 21, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

REGULATORY MILESTONES Basilea Pharmaceutica AG (SIX:BSLN) was up CHF0.35 to CHF97.90 last week after submitting an MAA to EMA for isavuconazole to treat invasive aspergillosis and invasive mucormycosis (zygomycosis). Partner Astellas Pharma Inc. (Tokyo:4503) submitted...
00:46 , Jul 16, 2014 |  BC Extra  |  Financial News

RestorGenex raises $35.6 million

RestorGenex Corp. (OTCQB:RESX) raised $35.6 million through the sale of 8.9 million units at $4 in a private placement to institutional investors, including Ally Bridge Group, and accredited investors. Each unit comprises a share and...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

Paloma, RestorGenex, VasculoMedics deal

Stratus Media Group Inc. merged with Paloma and VasculoMedics and subsequently changed its name to RestorGenex. The new company will focus on dermatology, ocular diseases and women's health. The merger was approved by the boards...
07:00 , Jun 10, 2013 |  BioCentury  |  Emerging Company Profile

ONL Therapeutics: Eyeing Fas

ONL Therapeutics LLC is developing a peptide antagonist of Fas-mediated apoptosis that could become the first pharmacotherapy to prevent vision loss associated with non-exudative retinal detachment. The company expects its products would be used as...
07:00 , Mar 14, 2011 |  BC Week In Review  |  Clinical News

Paloma preclinical data

In a mouse xenograft model of HRPC, Palomid 529 significantly reduced tumor volume vs. vehicle-treated controls at day 24 (p<0.05). Additionally, Palomid 529 plus cisplatin, Taxotere docetaxel or radiotherapy significantly reduced tumor volume compared to...
08:00 , Mar 7, 2011 |  BC Week In Review  |  Clinical News

Palomid 529: Phase I started

Paloma said the National Eye Institute began an open-label Phase I trial to evaluate 1.9 mg subconjunctival Palomid 529 every 4 weeks for 12 weeks in up to 7 patients. Paloma Pharmaceuticals Inc. , Jamaica...
08:00 , Feb 15, 2010 |  BC Week In Review  |  Clinical News

Palomid 529: Phase I start

Next quarter, Paloma plans to begin an open-label, U.S. Phase I trial to evaluate single intravitreal and subconjunctival injections of Palomid 529 in 33 patients. Paloma Pharmaceuticals Inc. , Jamaica Plain, Mass.   Product: Palomid...
08:00 , Feb 11, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes CREB-regulated transcription coactivator 2 (CRTC2; TORC2); cAMP responsive element binding protein 1 (CREB1; CREB) In vitro and mouse studies suggest that inhibiting CRTC2...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Clinical News

Paloma preclinical data

In mice, low (5.4 mg/kg) and high (54 mg/kg) doses of Palmoid 529 penetrated the blood brain barrier (BBB) with a brain-to-plasma ratio of >1. The low dose was slightly affected by P glycoprotein (...
07:00 , Jul 9, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Type 2 diabetes; obesity CREB-regulated transcription coactivator 2 (CRTC2; TORC2); activating transcription factor 6 (ATF6) A study in mice suggests that enhancing activity of...